Liquidia Technologies, Inc.

Contributing Author

Recent Articles by Liquidia Technologies, Inc.

Sep-03	FDA Grants Fast Track Designation to YUTREPIA for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis LQDA GlobeNewswire
Sep-02	Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress LQDA GlobeNewswire
Sep-01	Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference LQDA GlobeNewswire
Aug-12	Liquidia Corporation Reports Second Quarter 2026 Financial Results LQDA -10.52% GlobeNewswire
Jul-29	Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026 LQDA GlobeNewswire
Jun-11	Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions LQDA +9.77% GlobeNewswire
Jun-08	Liquidia Corporation Announces Inclusion in the S&P SmallCap 600 Index LQDA GlobeNewswire
May-27	Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference LQDA GlobeNewswire
May-11	Liquidia Corporation Reports First Quarter 2026 Financial Results LQDA +25.60% GlobeNewswire
May-06	Liquidia Corporation to Participate in Upcoming Investor Conferences LQDA +5.01% GlobeNewswire
May-04	Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026 LQDA GlobeNewswire
Apr-07	Liquidia Corporation to Participate in Upcoming Investor Conferences LQDA GlobeNewswire
Mar-05	Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update LQDA GlobeNewswire
Feb-26	Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026 LQDA GlobeNewswire
Jan-27	Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress LQDA GlobeNewswire
Jan-09	Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update LQDA +12.91% GlobeNewswire
Jan-07	Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference LQDA GlobeNewswire
Nov-03	Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences LQDA GlobeNewswire
Nov-03	Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update LQDA GlobeNewswire
Oct-27	Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 LQDA GlobeNewswire
Oct-07	Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 LQDA +5.10% GlobeNewswire
Sep-29	Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting LQDA GlobeNewswire
Sep-11	Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium LQDA GlobeNewswire
Aug-27	Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference LQDA GlobeNewswire
Aug-12	Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update LQDA +13.68% GlobeNewswire
Aug-05	Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 LQDA GlobeNewswire
Jun-23	Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA LQDA GlobeNewswire
Jun-02	Liquidia Schedules First Commercial Shipment of YUTREPIA (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD LQDA +13.07% GlobeNewswire
May-28	Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference LQDA -9.13% GlobeNewswire
May-23	U.S. FDA Approves Liquidia's YUTREPIA (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) LQDA GlobeNewswire

Liquidia Technologies, Inc.

Recent Articles by Liquidia Technologies, Inc.

Upgrade your Finviz experience